Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-526423 is an experimental small molecule belonging to the class of indolecarboxamides and derivatives. Its chemical formula is C24H24Cl2N4O4 and it has a molecular weight of approximately 503.38 g/mol. The compound has been identified as a structure-based inhibitor targeting glycogen phosphorylase B, suggesting its potential use in modulating glucose metabolism or related pathways. There are no approved indications or marketed uses for this drug; it remains at the experimental stage with no reported clinical trial activity beyond preclinical research[1][4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CP-526423.